INSIGHTS •   •   •   •   •   •   •   •   •   •   •  

Jan 18

Written by: Ken Kahtava
1/18/2013 12:03 PM  RssIcon

We celebrate the achievements, and the many lives saved and improved, since the ODA was passed 30 years ago. That said, contemporary issues that have great impact in today's rare disease drug development ecosystem, such as personalized medicine, over-extended payers and a number of other issues and advancements, were not on the radar in 1983. Where do we go from here?  Read this from FDA Matters for a good snapshot of ODA's success, and a look at the path forward.

Your name:
Gravatar Preview
Your email:
(Optional) Email used only to show Gravatar.
Your website:
Security Code
Enter the code shown above in the box below
Add Comment   Cancel